SCHEMBL6077550

SCHEMBL6077550

COC(=O)C(O)=CC(=O)N(Cc1ccccc1F)OC

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.43
KDM4E B2RXH2 2/20 0.43
KMT2A Q03164 5/20 0.41
MEN1 O00255 4/20 0.41
ATM Q13315 1/20 0.41
RIPK1 Q13546 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
GAA P10253 2/20 0.38
NPSR1 Q6W5P4 3/20 0.37
MAPT P10636 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
RAB9A P51151 1/20 0.36
LMNA P02545 2/20 0.36
HTT P42858 2/20 0.36
LTB4R Q15722 1/20 0.36
LTB4R2 Q9NPC1 1/20 0.36
POLB P06746 1/20 0.36
HCAR3 P49019 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6077547 1.00 ALDH1A1 (0.43) ALDH1A1KDM4EKMT2AMEN1ATM
SCHEMBL6877631 0.90 ALDH1A1 (0.48) ALDH1A1KDM4EKMT2AMEN1ATM
SCHEMBL6877629 0.90 ALDH1A1 (0.48) ALDH1A1KDM4EKMT2AMEN1ATM
SCHEMBL6077454 0.86 KMT2A (0.38) ALDH1A1KDM4EKMT2AMEN1GAA
SCHEMBL6077452 0.86 KMT2A (0.38) ALDH1A1KDM4EKMT2AMEN1GAA
SCHEMBL6413268 0.86 MEN1 (0.50) ALDH1A1KDM4EKMT2AMEN1ATM
SCHEMBL6413264 0.86 MEN1 (0.50) ALDH1A1KDM4EKMT2AMEN1ATM
SCHEMBL6077626 0.85 RIPK1 (0.41) ALDH1A1KDM4ERIPK1
SCHEMBL6078402 0.85 RIPK1 (0.41) ALDH1A1KDM4ERIPK1
SCHEMBL6078426 0.82 ATM (0.42) ALDH1A1KDM4EKMT2AMEN1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7109186-B2 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment BRISTOL-MYERS SQUIBB COMPANY (US) 2006-09-19 US disclosed
US-20040110804-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-06-10 US disclosed
WO-2004004657-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110804-A1 HIV integrase inhibitors CDKN1A, SAMHD1, CTCF ALDH1A1 563/4885KDM4E 702/4885KMT2A 736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.